Immunosuppression and Protective Immunity in Tumor Microenvironment

Dear Colleagues,

The tumor microenvironment (TME) is a dynamic ecosystem that includes not only cancer cells but also immune cells, stromal cells, as well as various tissue-resident cell types. Tumor microenvironments play crucial roles in tumor development, progression, and responses to treatment, including immunotherapy. In tumors, various mechanisms are involved in immunosuppressive microenvironments, including immunometabolism, immune checkpoint molecules, and immunosuppressive immune cells. On the other hand, the immune system comprises multiple factors able to provide comprehensive protective immune responses against tumors. The interplay between immunosuppression and protective immunity in the tumor microenvironment is critical for tumor development, and strategies aiming to overcome immunosuppression and enhance protective immune responses have been intensively developed recent years.  

We are pleased to invite you to submit your research paper to Cancers. This Special Issue aims to understand the role of immunoregulation in the TME as well as the genetic and epigenetic mechanisms in the TME. This Special Issue also aims to discuss updated knowledge and research on immune checkpoints, biomarkers, and therapy strategies.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Mechanisms of immunosuppression in the tumor microenvironment;

- Immune checkpoints and their role in tumor immunity;

- Immunotherapeutic strategies for overcoming immunotherapy resistance;

- Cellular and molecular interactions in the tumor microenvironment;

- Biomarkers for predicting immunosuppression and therapeutic response;

- Immunometabolism in the context of tumor immunity.

Prof. Dr. Yaoqi A. Wang
Dr. Fei Gao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• immune suppression
• tumor microenvironment
• protective immunity
• immune checkpoints
• immunotherapy
• cellular interactions
• molecular interactions
• biomarkers
• immunometabolism